Pharma

Your Article Summary

See Latest Articles

FDA Approves Boston Scientific's Next-Generation TAXUS Liberte Atom Stent System
Boston Scientific, 05/28/09

Boston Scientific Corporation announced it has received approval from the U.S. Food and Drug Administration to market its TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS Express Atom Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals